The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
Key facts
- Who runs it
- Herlev and Gentofte Hospital
- Where
- Denmark26 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 5,000 people, planned
- Started
- 1 Apr 2023
- Expected to end
- 31 Mar 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dabigatran Etexilate Oral Capsule
- Rivaroxaban Oral Tablet
- Edoxaban Oral Tablet
- Apixaban Oral Tablet
- Record updated
- 15 May 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization
- A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit
Who cannot take part
- A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for VTE
- Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC
- Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.
The 4 groups in the trial
- DabigatranExisting treatment, for comparison
After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Treatment: Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet, and Apixaban Oral Tablet
- RivaroxabanExisting treatment, for comparison
After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Treatment: Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet, and Apixaban Oral Tablet
- EdoxabanExisting treatment, for comparison
After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Treatment: Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet, and Apixaban Oral Tablet
- ApixabanExisting treatment, for comparison
After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
Treatment: Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet, and Apixaban Oral Tablet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism.
- Record updated
- 15 May 2025